Body composition and immunotherapy outcomes in patients with advanced urothelial carcinoma.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
212 patients (median age, 68 years; 75.
I · Intervention 중재 / 시술
atezolizumab and 18
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Routine CT-based body composition analysis may support risk stratification and guide early interventions. [SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15131-7.
[BACKGROUND] Abnormal body composition is associated with outcomes in patients receiving immune checkpoint inhibitors (ICIs), but its prognostic significance in advanced urothelial carcinoma (aUC) rem
- 95% CI 1.31–3.29
APA
Kim S, Yoon S, et al. (2025). Body composition and immunotherapy outcomes in patients with advanced urothelial carcinoma.. BMC cancer, 25(1), 1853. https://doi.org/10.1186/s12885-025-15131-7
MLA
Kim S, et al.. "Body composition and immunotherapy outcomes in patients with advanced urothelial carcinoma.." BMC cancer, vol. 25, no. 1, 2025, pp. 1853.
PMID
41339834 ↗
Abstract 한글 요약
[BACKGROUND] Abnormal body composition is associated with outcomes in patients receiving immune checkpoint inhibitors (ICIs), but its prognostic significance in advanced urothelial carcinoma (aUC) remains unclear. This study investigated the association between computed tomography (CT)-based body composition metrics and clinical outcomes in this population.
[METHODS] Patients with aUC treated with atezolizumab or pembrolizumab between January 2019 and December 2022 at our institution were retrospectively analysed. Body composition was assessed using abdomen–pelvis CT at the L3 vertebral level using artificial intelligence-based platform. Sarcopenia and myosteatosis were defined by T-scores below − 2.0. Visceral obesity (VO) was defined as visceral fat area ≥ 100 cm²; subcutaneous fat obesity (SFO) as subcutaneous fat area/height² ≥50 cm²/m² in men and 42 cm²/m² in women. Associations with overall survival (OS) and progression-free survival (PFS) were evaluated.
[RESULTS] Among 212 patients (median age, 68 years; 75.0% male), 82.0% received atezolizumab and 18.0% pembrolizumab. Sarcopenia and myosteatosis were present in 11.3% and 51.9%; VO and SFO in 61.3% and 42.0%. Sarcopenia and myosteatosis at baseline were significantly associated with shorter OS (HR 2.08; 95% CI, 1.31–3.29; = 0.002 and HR 1.54; 95% CI 1.14–2.07; = 0.004, respectively). In multivariable analysis, age < 70, haemoglobin < 10 g/dL, liver metastasis, sarcopenia (HR 2.26; 95% CI, 1.39–3.71; = 0.001) and myosteatosis (HR 1.49; 95% CI, 1.06–2.01; = 0.015) were independently associated with OS. Risk stratification based on the presence of sarcopenia and myosteatosis identified the highest mortality risk among patients with sarcopenia alone (HR 3.58; < 0.001), followed by those with both conditions (HR 2.15, = 0.015) and myosteatosis alone (HR 1.60, = 0.003), as compared with patients with neither condition. A model including sarcopenia and myosteatosis yielded modest discrimination (Harrell’s C-index, 0.601), which was improved with the addition of liver metastasis and hemoglobin level (Harrell’s C-index, 0.708). No body composition metric was associated with PFS.
[CONCLUSION] Sarcopenia and myosteatosis were significant independent prognostic factors for OS in ICI-treated aUC patients. Routine CT-based body composition analysis may support risk stratification and guide early interventions.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15131-7.
[METHODS] Patients with aUC treated with atezolizumab or pembrolizumab between January 2019 and December 2022 at our institution were retrospectively analysed. Body composition was assessed using abdomen–pelvis CT at the L3 vertebral level using artificial intelligence-based platform. Sarcopenia and myosteatosis were defined by T-scores below − 2.0. Visceral obesity (VO) was defined as visceral fat area ≥ 100 cm²; subcutaneous fat obesity (SFO) as subcutaneous fat area/height² ≥50 cm²/m² in men and 42 cm²/m² in women. Associations with overall survival (OS) and progression-free survival (PFS) were evaluated.
[RESULTS] Among 212 patients (median age, 68 years; 75.0% male), 82.0% received atezolizumab and 18.0% pembrolizumab. Sarcopenia and myosteatosis were present in 11.3% and 51.9%; VO and SFO in 61.3% and 42.0%. Sarcopenia and myosteatosis at baseline were significantly associated with shorter OS (HR 2.08; 95% CI, 1.31–3.29; = 0.002 and HR 1.54; 95% CI 1.14–2.07; = 0.004, respectively). In multivariable analysis, age < 70, haemoglobin < 10 g/dL, liver metastasis, sarcopenia (HR 2.26; 95% CI, 1.39–3.71; = 0.001) and myosteatosis (HR 1.49; 95% CI, 1.06–2.01; = 0.015) were independently associated with OS. Risk stratification based on the presence of sarcopenia and myosteatosis identified the highest mortality risk among patients with sarcopenia alone (HR 3.58; < 0.001), followed by those with both conditions (HR 2.15, = 0.015) and myosteatosis alone (HR 1.60, = 0.003), as compared with patients with neither condition. A model including sarcopenia and myosteatosis yielded modest discrimination (Harrell’s C-index, 0.601), which was improved with the addition of liver metastasis and hemoglobin level (Harrell’s C-index, 0.708). No body composition metric was associated with PFS.
[CONCLUSION] Sarcopenia and myosteatosis were significant independent prognostic factors for OS in ICI-treated aUC patients. Routine CT-based body composition analysis may support risk stratification and guide early interventions.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15131-7.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Size matters: Establishing a cut-off for rectal neuroendocrine neoplasm to predict recurrence and standardize surveillance guidelines.
- Immunoresistant to immunosensitive - Histotripsy's unique potential to overcome resistance.
- Secondary Cancer Risk in Breast Cancer with and without Radiotherapy: The Observational Health Data Sciences and Informatics (OHDSI) Cohort Study.
- Fertility treatment and risk of non-gynecological cancer: a systematic review.
- Robust Multimodal Deep Learning for Lymphoma Subtype Classification Using F-FDG PET Maximum Intensity Projection Images and Clinical Data: A Multi-Center Study.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy.
- Novel roles of SETD2 in tumor metabolism and immunotherapy: a systematic review and meta-analysis.
- Negative trial but positive lesson: reframing immunotherapy resistance from one-size-fits-all to precision strategies.
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy.
- Copper-enriched zinc peroxides induced cuproptosis through concurrent metabolic and oxidative dysregulation for boosting immunotherapy in colorectal cancer.